字号·· | 护眼
加拿大广播公司

乙型肝炎治愈是否指日可待?新药带来希望,但“仍有很长的路要走”Is a cure on the horizon for hepatitis B? New drug offers hope, but there's a 'long way to go'

点「原文对照」整页切到原文,或双击某段只看那段的原文。

乙型肝炎病毒(如图所示)可导致慢性肝病。11月上旬,加拿大卫生部批准了一种突破性药物,为部分患者提供了首个“功能性治愈”方案,不过关于获取途径、成本以及药效持续时间等重大问题依然存在。(美国疾病控制与预防中心)Hepatitis B virus, shown here, can lead to chronic liver disease. In early November, Health Canada approved a breakthrough drug offering the first 'functional cure' for some patients, though major questions remain about access, cost and how long its impacts last. (U.S. Centers for Disease Control an

尽管经过了几十年消除乙型肝炎的努力,这种病毒性肝炎仍然是一个无声的威胁,而且长期以来一直缺乏治愈方法。

Despite decades of efforts to wipe out hepatitis B, the viral liver infection remains a quiet threat — and one that's long lacked a cure.

虽然自儿童疫苗接种项目兴起以来,感染率已大幅下降,但据估计仍有26万加拿大人感染该病毒,其中大约有一半人不知道自己已经感染。随着时间推移,许多默默携带病毒的人最终会出现一系列危及生命的问题,包括癌症或突发性肝衰竭。人们期盼已久的治愈方法终于有望实现了吗?

While rates have dropped dramatically since the rise of childhood vaccination programs, an estimated 260,000 Canadians are still living with the virus, including roughly half who don't know they're infected Over time, many of those silently carrying the virus go on to develop a range of life-threatening issues, including cancer or sudden liver failure. Could a long-awaited cure finally be in sight?

11月上旬,加拿大卫生部批准了一种突破性药物,为部分慢性乙型肝炎患者提供了首个“功能性治愈”方案。该药的制造商葛兰素史克公司预计将于2027年初推出该药。卡尔加里大学卡明医学院的肝病学家兼教授卡拉·科芬博士称其为“向前迈出的重大一步”。同时,她警告称,该药物仅对一小部分乙型肝炎患者有效,而且在费用、获取途径以及这种强效新疗法的作用能持续多久等方面,依然存在疑问。

In early November, Health Canada approved a breakthrough drug offering the first "functional cure" for a portion of chronic hepatitis B patients, which drugmaker GSK expect to roll out in early 2027 Dr. Carla Coffin, a hepatologist and professor at the University of Calgary's Cumming School of Medicine, calls it a "major step forward." At the same time, she warned it's only effective in a relatively small proportion of people with hepatitis B — and questions remain around cost, access and just how long the impacts of the powerful new treatment last.

病毒可导致慢性肝部感染 乙型肝炎病毒通过受感染的体液传播,包括血液、精液和阴道分泌物,这使其既是一种性传播感染,也是一种可由母婴传播或通过受污染的注射吸毒器具(如针头)传播的病毒。

Virus can lead to chronic liver infection The hepatitis B virus spreads through infected bodily fluids, including blood, semen and vaginal fluids, making it both a sexually-transmitted infection and one that passes from mother-to-child, or via contaminated drug-injection equipment like needles.

大多数感染该病毒的健康成年人能够自行清除病毒并获得终身免疫。

Most healthy adults who contract the virus clear it on their own and develop lifelong immunity.

但当一个人在婴儿期或儿童期感染乙型肝炎时,它可能会演变成慢性感染,对肝脏造成长期损害和炎症,从而导致严重的并发症或死亡。

But when someone contracts hepatitis B as an infant or during childhood, it can become a chronic infection that causes long-term damage and inflammation to the liver, leading to serious complications or death.

加拿大疫苗咨询委员会表示,所有婴儿都应接种乙肝疫苗 音频 加拿大卫生部批准首个慢性乙型肝炎“功能性治愈”药物 这些感染的负担不成比例地由某些群体承担。

All infants should be vaccinated against hep B, says Canadian vaccine advisory committee Audio Health Canada approves first "functional cure" for Chronic Hepatitis B The burden of these infections is disproportionately carried by certain populations.

原住民社区、非法药物使用者、从事高风险性行为的个人以及来自乙型肝炎高发国家的移民,其感染率更高。

There are higher rates among Indigenous communities, illicit drug users, individuals engaging in high-risk sexual activity and immigrants from countries where hepatitis B is more common.

渥太华医院病毒性肝炎项目负责人柯蒂斯·库珀(Curtis Cooper)医生解释说,在此之前,患者需要长期进行抗病毒治疗来抑制病毒。

Up until now, patients have required long-term antiviral therapy to surpress the virus, explained Dr. Curtis Cooper, who leads the Ottawa Hospital's viral hepatitis program.

他说:“这种新疗法能彻底清除血液中所有的乙型肝炎病毒标志物,”并指出它为那些希望停止其他治疗的患者提供了“相当大的希望”。

"This new treatment, it completely clears all of the viral markers for hepatitis B out of the blood," he said, noting it offers "quite a bit of hope" for patients aiming to discontinue other treatments.

渥太华早间药物可能取代长期抗病毒治疗 这种名为bepirovirsen的药物是一个短期的注射疗程,可以使部分患者体内的病毒DNA水平降至检测不到的程度。

Ottawa Morning Drug may replace long-term antiviral treatment The drug, called bepirovirsen, is a short-term course of injections which can lead to undetectable levels of virus DNA in some patients.

卡尔加里的科芬(Coffin)表示:“从我们目前拥有的数据来看,如果它有效,那么我们就可以向(患者)保证,他们已经实现了功能性治愈,未来不需要再进行任何乙型肝炎治疗。”

"From the data that we have now, if it works, then we can reassure [patients] that they have a functional cure and they won't need to take any further hepatitis B treatments in the future," said Coffin, from the University of Calgary.

这些数据基于将该药物与安慰剂进行对比的临床试验。试验显示,在停止所有其他乙型肝炎治疗24周后,约有五分之一的患者仍能控制病毒,其血液中的病毒水平检测不到。

The data is based on clinical trials comparing the drug to a placebo, which showed around one-fifth of patients still had the virus under control 24 weeks after stopping all other hepatitis B treatments, with undetectable levels in their blood.

医生与肝脏专家组队在艾伯塔省更好地抗击肝炎 研究表明,全球八分之一的癌症病例由感染引起 科芬强调,该药物仅对少数患者有效,“临床医生必须非常仔细地决定哪些患者有资格接受治疗,哪些患者能从中受益。”科芬指出,例如,有肝硬化病史的个人不符合条件。肝硬化是指健康的肝脏组织永久受损并出现瘢痕、阻碍正常血流的情况。她补充说,与每日服用抗病毒药物相比,注射该药物可能会产生更多的副作用,包括皮疹。

Doctors, liver specialist team up to better fight hepatitis in Alberta 1 in 8 cancer cases worldwide is caused by infections, study suggests The drug works only for a minority of patients, Coffin stressed, and "clinicians have to very carefully decide on which patients would be eligible and which would benefit from the treatment." For instance, individuals with a history of cirrhosis — where healthy liver tissue is permanently scarred, blocking normal blood flow — don't qualify, Coffin noted. She added there can be more side effects from the shot, including a rash, compared to taking a daily anti-viral medication.

目前也不清楚这种疗法的持久性究竟如何。科芬表示,随着临床试验结束以来时间的推移,相关数据仍在不断涌现,最新数据显示该药物的持久疗效至少可达96周。

It's also not clear just how durable the treatment will be. Coffin says data is still emerging as more time passes since the clinical trials, with the latest figures showing the drug has a lasting impact of at least 96 weeks.

科芬说:“我们的预期是它会持续有效。但当然,在对这些患者进行长期随访之前,我们不会知道结果。”

"Our expectation is that it will last," Coffin said. "But of course, we won't know that until we do the long-term follow-up in these patients."

2025年12月5日 疾控中心小组投票叫停婴儿乙肝疫苗接种被称为“不负责任” 成本与获取途径成疑问不列颠哥伦比亚大学胃肠病学分部医学教授埃里克·吉田博士对该药物在乙型肝炎治疗的整体格局中处于什么位置持怀疑态度。

CDC panel vote to stop hep B vaccine for babies called 'irresponsible' December 5, 2025 Duration Questions around cost, access Dr. Eric Yoshida, a professor of medicine in the division of gastroenterology at the University of British Columbia, is skeptical of where the drug fits into the broader landscape for hepatitis B treatments.

虽然他承认bepirovirsen是一项重大的科学飞跃,但他表示,获取途径和成本可能会成为普及的障碍——这意味着该药物可能无法惠及许多加拿大人。

While he agreed bepirovirsen offers a major scientific leap forward, he says access and cost could be barriers to uptake — meaning the drug may not reach many Canadians.

特朗普签署行政令呼吁减少儿童疫苗接种 加拿大新增艾滋病感染人数上升 倡导者称多年来取得的进展面临风险吉田表示,在日本,该药物获批较早,一个疗程的费用约为8.4万加元。尽管加拿大的实际定价尚不明确,但他质疑私人药物计划和各省最终是否会将其纳入报销范围。

Trump signs executive order calling for fewer childhood vaccinations New HIV infections in Canada are rising. Advocates say years of progress are at risk In Japan, where the drug was approved earlier, Yoshida says a course of therapy costs roughly $84,000 Cdn. Though actual pricing for Canada isn't yet clear, he questioned whether private drug plans and the provinces will end up covering it.

吉田说:“展望未来,好吧,这是第一代。下一代可能会更好,成本也会更低,所以我认为未来是光明的。”

"Looking into the future, well, this is the first generation. The next generation is probably going to be even better and even less expensive, so I think the future is looking bright," Yoshida said.

“但我想对于普通的加拿大乙肝患者来说,它可能不会有多大意义。” 2024年10月15日 西北地区牙科患者可能接触过艾滋病毒和肝炎,他们希望改善护理 加拿大呼吁实行全民婴儿接种撇开治疗可能性不谈,科芬和吉田都强调,需要提高人们对乙肝疫苗接种的认识,以此作为彻底根除该病毒的途径。然而,针对该病毒的全球免疫计划仍然充满困难。

"But I think for the average Canadian patient with hepatitis B, it's probably not going to mean a heck of a lot." N.W.T. dental patients possibly exposed to HIV and hepatitis want to see improved care October 15, 2024 Canada calls for universal infant vaccination Treatment possibilities aside, both Coffin and Yoshida stressed the need for more awareness of hepatitis B vaccination as a way to stamp out the virus for good. Yet global immunization programs for this virus remain fraught.

11月,加拿大的疫苗顾问针对所有加拿大婴儿接种乙肝疫苗发布了一项新建议,这可能在未来使各省实现统一,此前这些省份提供的接种年龄各不相同,从婴儿期到六年级或七年级的儿童不等。

In November, Canada's vaccine advisors issued a new recommendation for all Canadian infants to receive the hepatitis B shot which may — in time — align provinces that offer the shot at a mix of ages, from infancy to children in grades six or seven.

吉田表示:“如果世界上每个国家都为其新生儿接种疫苗,我认为乙型肝炎基本上就会被消灭。”但加拿大最近的举措与美国形成了鲜明对比,美国疾病控制与预防中心(CDC)在2025年底取消了其实行已久针对新生儿的普遍乙肝疫苗接种建议。

"If every country in the world vaccinated their newborns," said Yoshida, "I think hepatitis B would be basically on the way out." But Canada's recent move is a stark contrast from the U.S., where the Centers for Disease Control and Prevention (CDC) removed its longstanding universal hepatitis B vaccination recommendation for newborns in late 2025.

许多国家也在乙肝免疫接种方面面临困难,导致某些地区的慢性感染率显著升高。世界卫生组织的数据显示,2024年,全球所有与乙肝相关的死亡病例中,有75%发生在非洲和西太平洋地区。科芬表示:“我们仍有很长的路要走。”

Many countries also struggle with hepatitis B immunization, leading to significantly higher rates of chronic infection in certain regions. In 2024, 75 per cent of all global hepatitis B-related deaths were across Africa and the Western Pacific, World Health Organization data shows "We still have a long way to go," Coffin said.

阅读媒体原文 ↗